OncLive TV

Irene Ghobrial, MD, discusses the potential utility of triplet therapy in smoldering multiple myeloma.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Karen E. Knudsen, PhD, discusses the rationale for investigating DNA-dependent protein kinase as a target in prostate cancer.

Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternate delivery models for genetic counseling in prostate cancer.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Andrew Branagan, MD, discusses the results of the phase 3 TOURMALINE-MM3 trial in multiple myeloma.

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternative delivery models for genetic counseling in prostate cancer.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Lloyd B. Gayle, MD, discusses current treatment options for patients who develop breast implant–associated anaplastic large cell lymphoma (ALCL).

Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

David P. Carbone, MD, PhD, discusses the importance of personalizing immunotherapy for patients with non–small cell lung cancer.

Andre Goy, MD, MS, discusses the evolution of treatment selection in mantle cell lymphoma.

James N. Gerson, MD, discusses clinical trial accrual in mantle cell lymphoma.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Marc J. Braunstein, MD, PhD, discusses updated results from the GRIFFIN trial in multiple myeloma.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.

John P. Sfakianos, MD, discusses the importance of restaging transurethral resection of bladder tumors.